Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 15/20 | 0.47 |
| ▸ | GRM5 | P41594 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10318557 | 1.00 | GCK (0.47) | GCKGRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL10320244 | 1.00 | GCK (0.47) | GCKGRM5CYP3A4DRD3SLC6A3 | |
| SCHEMBL1271044 | 0.92 | GCK (0.41) | GCK | |
| SCHEMBL15252311 | 0.92 | GCK (0.41) | GCK | |
| SCHEMBL15252276 | 0.92 | GCK (0.41) | GCK | |
| SCHEMBL10317964 | 0.91 | MAPT (0.46) | GCK | |
| SCHEMBL10318380 | 0.91 | MAPT (0.46) | GCK | |
| SCHEMBL10317965 | 0.91 | MAPT (0.46) | GCK | |
| SCHEMBL15252416 | 0.89 | RAB9A (0.46) | GCK | |
| SCHEMBL15252528 | 0.89 | RAB9A (0.46) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835469-B2 | Substituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2014-09-16 | — | — | US | claimed |
| EP-2459554-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LTD (IN) | 2013-09-18 | — | — | EP | claimed |
| US-20120184544-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-07-19 | — | — | US | claimed |
| US-8835469-B2 | Substituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2014-09-16 | — | — | US | disclosed |
| EP-2459554-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LTD (IN) | 2013-09-18 | — | — | EP | disclosed |
| US-20120184544-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184544-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | GCKR, GCK, GK | GCK 2/4885GRM5 1963/4885CYP3A4 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.